Developer docs
API playgroundTry for free, no card

Search company profiles

Enveric Biosciences

Full company profile

uuid0000ur5

Namestring
Enveric Biosciences
Legal namestring
Enveric Biosciences, Inc.
Websiteurl
enveric.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Enveric Biosciences, Inc. (NASDAQ: ENVB) is a development-stage biotechnology company developing neuroplastogenic small-molecule therapeutics for neuropsychiatric disorders including PTSD, treatment-resistant depression, major depressive disorder, and generalized anxiety disorder. The company's core technology is the Psybrary™ platform — a proprietary discovery and development engine that has synthesized hundreds of novel molecules derived from classic psychedelics (DMT, psilocybin, MDMA) with engineered receptor binding profiles. Its lead candidate, EB-003, is designed to selectively engage both 5-HT2A and 5-HT1B receptors to deliver antidepressant and anxiolytic effects without hallucinogenic effects, enabling a prescription model with outpatient administration. Additional pipeline series include EVM301 (carboxylated psilocybin derivatives) and EVM401 (mescaline-derived phenylalkylamines and indolethylamines).

The business model is structured around two revenue paths. First, Enveric out-licenses non-core Psybrary™ assets to pharmaceutical partners — including MycoMedica Life Sciences (EB-002, up to $62M in potential milestones), Aries Science & Technology (topical radiation dermatitis product, up to $61M), Restoration Biologics (cannabinoid-COX-2 conjugates, up to $82M), and TOTEC Pharma (RCANN™ trademark) — generating future milestone and royalty revenue. Second, the company intends to commercialize its core neuroplastogens directly via a prescription model for mental health indications once regulatory approval is secured. The Psybrary™ IP estate is protected by 27 issued U.S. patents and approximately 60 pending applications.

Enveric is operationally lean with 1-10 employees, dual-shore research operations across Cambridge, MA (HQ, relocated from Naples, FL in 2025), Calgary, AB, and Adelaide, Australia (via subsidiary Enveric Therapeutics, Pty. Ltd.), and a market capitalization of approximately $5.5M as of June 2026 on 4.03M shares outstanding at $1.37. The company funds operations through frequent small equity offerings and warrant exercises — $12.2M in gross proceeds during fiscal 2025 and a $5M private placement in April 2026 — while carrying a $1.6M quarterly net loss and $10.3M cash on hand as of mid-May 2026.

Short descriptiontext

Enveric Biosciences is a clinical-stage biotechnology company (NASDAQ: ENVB) developing neuroplastogenic small-molecule therapeutics for PTSD, treatment-resistant depression, and anxiety, using its proprietary Psybrary™ platform of psychedelic-derived compounds to enable non-hallucinogenic, outpatient prescription treatments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuroplastogenic therapeutics, psychedelic-derived pharmaceuticals, mental health drug discovery, cannabinoid biopharmaceuticals, novel tryptamine derivatives
Industry1 code
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Psychiatric Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Revenue
TypeLicensing Royalties
Description

Out-licensing Psybrary™ assets generates milestone payments and royalty revenue. Licensing agreements include MycoMedica Life Sciences ($62M potential milestones for EB-002), Aries Science & Technology ($61M potential milestones for Topical Product), and Restoration Biologics ($82M potential milestones for Cannabinoid-COX-2 Conjugate Compounds).

enveric.com
2Pharmaceutical Product Sales
TypeOne Time License
Description

Once products receive regulatory approval, the company plans to commercialize neuroplastogenic therapeutics through prescription model for mental health disorders.

enveric.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Psybrary
Description

The company's unique discovery and development platform containing a robust IP portfolio of novel molecules for specific mental health indications

enveric.com
+2 more records
Core offering1 text field

Enveric Biosciences is a pre-commercial biotechnology company developing neuroplastogenic small-molecule therapeutics for neuropsychiatric disorders. Its lead candidate EB-003 is designed to selectively engage 5-HT2A and 5-HT1B receptors to deliver fast-acting antidepressant and anxiolytic effects without hallucinogenic activity. The company leverages The Psybrary™ discovery platform to generate proprietary molecules, with multiple candidates out-licensed to pharmaceutical partners for development in radiation dermatitis, cannabinoid-COX-2 conjugates, and other indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Single dose of EB-003 significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05) in validated preclinical PTSD model
+2 more records
Product overview1 text field

Enveric Biosciences is a biotechnology company developing a portfolio of neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. The core product is EB-003, a lead molecule in clinical development targeting dual 5-HT2A and 5-HT1B receptors. The company operates The Psybrary™, a discovery platform that has generated multiple drug candidate series including EVM301 (carboxylated psilocybin derivatives) and EVM401 (mescaline-derived compounds). Several assets have been out-licensed to partners including MycoMedica Life Sciences (EB-002), Aries Science & Technology (topical radiation dermatitis product), and Restoration Biologics (cannabinoid-COX-2 conjugates). The company is headquartered in Cambridge, MA with offices in Calgary, AB and Naples, FL.

Product and service7 records
1EB-003
CategoryLead Drug Candidate
Description

Neuroplastogenic small-molecule therapeutic designed to selectively engage both 5-HT2A and 5-HT1B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects without hallucinogenic effects. Indicated for difficult-to-treat mental health disorders including PTSD, treatment-resistant depression, and generalized anxiety disorder, with a planned outpatient prescription model.

2EVM401 Series
CategoryDrug Candidate Series
Description

Series of novel phenylalkylamines and indolethylamines, including mescaline-derived compounds, demonstrating promising interactions with key brain receptors involved in mental health disorders and addiction. Being developed for potential treatment of opioid withdrawal, ADHD, anxiety, depression, and substance use disorders.

3EVM301 Series
CategoryDrug Candidate Series
Description

Carboxylated psilocybin derivatives developed as neuroplastogenic molecules targeting neuropsychiatric and addiction disorders, designed to promote neuroplasticity while reducing or eliminating hallucinations. Covered by issued composition-of-matter and methods patents.

4Psybrary™ Discovery Platform
CategoryDiscovery Platform
Description

Proprietary discovery and development platform that has generated a robust intellectual property portfolio of novel synthetic derivatives of classic psychedelics (DMT, psilocybin, MDMA) with unique receptor binding profiles and pharmacokinetic properties for specific mental health indications. Platform assets are made available for partnering or out-licensing to pharmaceutical companies.

5EB-002 (Out-Licensed to MycoMedica Life Sciences)
CategoryOut-Licensed Asset
Description

Drug candidate out-licensed to MycoMedica Life Sciences with up to $62 million in potential milestone payments plus tiered single-digit royalties. Specific indication detail not provided in source.

6Topical Product for Radiation Dermatitis (Out-Licensed to Aries Science & Technology)
CategoryOut-Licensed Asset
Description

Topical pharmaceutical product licensed to Aries Science & Technology for development in radiation dermatitis, with up to $61 million in potential milestone payments plus tiered royalties ranging from 2.5% to 10%.

7Cannabinoid-COX-2 Conjugate Compounds (Out-Licensed to Restoration Biologics)
CategoryOut-Licensed Asset
Description

Cannabinoid-COX-2 conjugate compounds licensed to Restoration Biologics LLC under two agreements covering pharmaceutical and potential non-pharmaceutical applications for joint disease treatment. Deal terms include up to $82 million in potential milestone payments plus tiered single to low double-digit royalties.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1MagicMed Industries
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-24
Description

Enveric acquired MagicMed Industries in an all-stock transaction to expand its pipeline of cannabinoid and psychedelic therapies. MagicMed's Psybrary™ platform contributed to Enveric's discovery and development capabilities for creating psychedelic-derived molecules for oncology and CNS disorders including PTSD.

prnewswire.com
2MycoMedica Life Sciences
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensing agreement for EB-002, a topical product for radiation dermatitis. Deal terms include up to $62 million in potential milestone payments plus tiered single digit royalties.

enveric.com
3Aries Science & Technology
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensing agreement for Topical Product for Radiation Dermatitis. Deal terms include up to $61 million in potential milestone payments plus tiered royalties ranging from 2.5% to 10%.

enveric.com
4Restoration Biologics LLC
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Two licensing agreements for Cannabinoid-COX-2 conjugate compounds for pharmaceutical and potential non-pharmaceutical applications. Deal terms include up to $82 million in potential milestone payments plus tiered single to low double digit royalties.

enveric.com
5TOTEC Pharma LLC
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Enveric subsidiary Akos Biosciences licensed the RCANN trademark portfolio to TOTEC Pharma for development of patented cannabinoid crème technology for radiation dermatitis. Agreement grants option to purchase trademark portfolio upon meeting specific development and commercialization milestones.

in.investing.com
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Intellectual property law firm hired by Enveric to contest a Post-Grant Review petition filed by Gilgamesh Pharmaceuticals against Enveric's patent relevant to bretisilocin molecule acquired by AbbVie in $1.2 billion deal.

Strategic tierMinorTypeOthers
Description

Following AbbVie's acquisition of Gilgamesh Pharmaceuticals in October 2025, AbbVie withdrew the Post-Grant Review petition filed by Gilgamesh against Enveric's patent covering halogenated psilocybin derivatives. This action left no remaining challenges against Enveric's patent.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage company developing psilocybin therapy for treatment-resistant depression. Directly comparable to Enveric as a psychedelic-inspired CNS therapeutics developer targeting overlapping mental health indications, with later-stage assets.

2MindMed
TypeDirect peer
Description

Clinical-stage neuroplastogenic medicine developer with a pipeline of LSD and MDMA-derived candidates for anxiety, depression, and ADHD. Closely comparable to Enveric's neuroplastogen CNS focus with similar target indications and small-molecule strategy.

3atai Life Sciences
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health, including DMT-based treatments. Directly comparable to Enveric in psychedelic-inspired CNS drug development and out-licensing/partnering model.

TypeDirect peer
Description

Clinical-stage company developing DMT-based therapies (GH001) for treatment-resistant depression. Comparable to Enveric's neuroplastogenic approach with overlapping 5-HT2A receptor mechanism and same TRD target indication.

TypeDirect peer
Description

Clinical-stage company developing deuterated psilocybin analogs (CYB003) for depression and other CNS indications. Directly comparable to Enveric's psychedelic-derived small-molecule CNS strategy and analogous chemistry-platform approach.

TypeBroad incumbent
Description

Large pharmaceutical company that acquired Gilgamesh Pharmaceuticals (bretisilocin) for ~$1.2B in October 2025, validating the psychedelic-inspired CNS therapeutic class. Comparable as a competitor/partner in the same therapeutic space and relevant acquirer for Enveric's patent estate.

TypeDirect peer
Description

Developed Zurzuvae (zuranolone) for postpartum depression and other CNS neuroactive steroid therapies. Comparable to Enveric as a small-molecule CNS therapeutics developer targeting depression and related neuropsychiatric indications.

TypeDirect peer
Description

Commercial-stage CNS biopharmaceutical company with Auvelity (dextromethorphan-bupropion) approved for major depressive disorder. Comparable to Enveric's CNS focus on depression/anxiety with an oral, outpatient prescription model analogous to Enveric's planned EB-003 positioning.

TypeDirect peer
Description

Clinical-stage CNS company developing psychedelic-inspired treatments including NRX-101 for suicidal bipolar depression and DMT-based therapies. Directly comparable to Enveric in psychedelic-derived CNS therapeutics with overlapping TRD/suicidality target indications.

TypeBroad incumbent
Description

Clinical-stage CNS biopharmaceutical company developing precision neuroscience therapeutics for depression and other neuropsychiatric disorders. Comparable to Enveric as a CNS-focused small-molecule developer with similar target indications and prescription-model strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enveric Biosciences

Psychiatric Therapeuticsenveric.com

Enveric Biosciences is a clinical-stage biotechnology company (NASDAQ: ENVB) developing neuroplastogenic small-molecule therapeutics for PTSD, treatment-resistant depression, and anxiety, using its proprietary Psybrary™ platform of psychedelic-derived compounds to enable non-hallucinogenic, outpatient prescription treatments.

What Enveric Biosciences does

Enveric Biosciences, Inc. (NASDAQ: ENVB) is a development-stage biotechnology company developing neuroplastogenic small-molecule therapeutics for neuropsychiatric disorders including PTSD, treatment-resistant depression, major depressive disorder, and generalized anxiety disorder. The company's core technology is the Psybrary™ platform — a proprietary discovery and development engine that has synthesized hundreds of novel molecules derived from classic psychedelics (DMT, psilocybin, MDMA) with engineered receptor binding profiles. Its lead candidate, EB-003, is designed to selectively engage both 5-HT2A and 5-HT1B receptors to deliver antidepressant and anxiolytic effects without hallucinogenic effects, enabling a prescription model with outpatient administration. Additional pipeline series include EVM301 (carboxylated psilocybin derivatives) and EVM401 (mescaline-derived phenylalkylamines and indolethylamines).

The business model is structured around two revenue paths. First, Enveric out-licenses non-core Psybrary™ assets to pharmaceutical partners — including MycoMedica Life Sciences (EB-002, up to $62M in potential milestones), Aries Science & Technology (topical radiation dermatitis product, up to $61M), Restoration Biologics (cannabinoid-COX-2 conjugates, up to $82M), and TOTEC Pharma (RCANN™ trademark) — generating future milestone and royalty revenue. Second, the company intends to commercialize its core neuroplastogens directly via a prescription model for mental health indications once regulatory approval is secured. The Psybrary™ IP estate is protected by 27 issued U.S. patents and approximately 60 pending applications.

Enveric is operationally lean with 1-10 employees, dual-shore research operations across Cambridge, MA (HQ, relocated from Naples, FL in 2025), Calgary, AB, and Adelaide, Australia (via subsidiary Enveric Therapeutics, Pty. Ltd.), and a market capitalization of approximately $5.5M as of June 2026 on 4.03M shares outstanding at $1.37. The company funds operations through frequent small equity offerings and warrant exercises — $12.2M in gross proceeds during fiscal 2025 and a $5M private placement in April 2026 — while carrying a $1.6M quarterly net loss and $10.3M cash on hand as of mid-May 2026.

Enveric Biosciences firmographics

Firmographics
Name
Enveric Biosciences
Legal name
Enveric Biosciences, Inc.
Website
https://enveric.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Enveric Biosciences is a clinical-stage biotechnology company (NASDAQ: ENVB) developing neuroplastogenic small-molecule therapeutics for PTSD, treatment-resistant depression, and anxiety, using its proprietary Psybrary™ platform of psychedelic-derived compounds to enable non-hallucinogenic, outpatient prescription treatments.
Ownership category
akta.pro rank

Enveric Biosciences industry classification

Industry
Product category
Psychiatric Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Neuroplastogenic therapeutics
  • Psychedelic-derived pharmaceuticals
  • Mental health drug discovery
  • Cannabinoid biopharmaceuticals
  • Novel tryptamine derivatives

Where Enveric Biosciences is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Enveric Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing Revenue: Out-licensing Psybrary™ assets generates milestone payments and royalty revenue. Licensing agreements include MycoMedica Life Sciences ($62M potential milestones for EB-002), Aries Science & Technology ($61M potential milestones for Topical Product), and Restoration Biologics ($82M potential milestones for Cannabinoid-COX-2 Conjugate Compounds).
  2. Pharmaceutical Product Sales: Once products receive regulatory approval, the company plans to commercialize neuroplastogenic therapeutics through prescription model for mental health disorders.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Enveric Biosciences product offering

Product offering

Core offering

Enveric Biosciences is a pre-commercial biotechnology company developing neuroplastogenic small-molecule therapeutics for neuropsychiatric disorders. Its lead candidate EB-003 is designed to selectively engage 5-HT2A and 5-HT1B receptors to deliver fast-acting antidepressant and anxiolytic effects without hallucinogenic activity. The company leverages The Psybrary™ discovery platform to generate proprietary molecules, with multiple candidates out-licensed to pharmaceutical partners for development in radiation dermatitis, cannabinoid-COX-2 conjugates, and other indications.

Product overview

Enveric Biosciences is a biotechnology company developing a portfolio of neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. The core product is EB-003, a lead molecule in clinical development targeting dual 5-HT2A and 5-HT1B receptors. The company operates The Psybrary™, a discovery platform that has generated multiple drug candidate series including EVM301 (carboxylated psilocybin derivatives) and EVM401 (mescaline-derived compounds). Several assets have been out-licensed to partners including MycoMedica Life Sciences (EB-002), Aries Science & Technology (topical radiation dermatitis product), and Restoration Biologics (cannabinoid-COX-2 conjugates). The company is headquartered in Cambridge, MA with offices in Calgary, AB and Naples, FL.

Differentiator

Problem solved

Functional benefit

Brands

  • Psybrary: The company's unique discovery and development platform containing a robust IP portfolio of novel molecules for specific mental health indications
  • EB-003
  • EVM401

Products and services

  • EB-003 Neuroplastogenic small-molecule therapeutic designed to selectively engage both 5-HT2A and 5-HT1B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects without hallucinogenic effects. Indicated for difficult-to-treat mental health disorders including PTSD, treatment-resistant depression, and generalized anxiety disorder, with a planned outpatient prescription model.
  • EVM401 Series Series of novel phenylalkylamines and indolethylamines, including mescaline-derived compounds, demonstrating promising interactions with key brain receptors involved in mental health disorders and addiction. Being developed for potential treatment of opioid withdrawal, ADHD, anxiety, depression, and substance use disorders.
  • EVM301 Series Carboxylated psilocybin derivatives developed as neuroplastogenic molecules targeting neuropsychiatric and addiction disorders, designed to promote neuroplasticity while reducing or eliminating hallucinations. Covered by issued composition-of-matter and methods patents.
  • Psybrary™ Discovery Platform Proprietary discovery and development platform that has generated a robust intellectual property portfolio of novel synthetic derivatives of classic psychedelics (DMT, psilocybin, MDMA) with unique receptor binding profiles and pharmacokinetic properties for specific mental health indications. Platform assets are made available for partnering or out-licensing to pharmaceutical companies.
  • EB-002 (Out-Licensed to MycoMedica Life Sciences) Drug candidate out-licensed to MycoMedica Life Sciences with up to $62 million in potential milestone payments plus tiered single-digit royalties. Specific indication detail not provided in source.
  • Topical Product for Radiation Dermatitis (Out-Licensed to Aries Science & Technology) Topical pharmaceutical product licensed to Aries Science & Technology for development in radiation dermatitis, with up to $61 million in potential milestone payments plus tiered royalties ranging from 2.5% to 10%.
  • Cannabinoid-COX-2 Conjugate Compounds (Out-Licensed to Restoration Biologics) Cannabinoid-COX-2 conjugate compounds licensed to Restoration Biologics LLC under two agreements covering pharmaceutical and potential non-pharmaceutical applications for joint disease treatment. Deal terms include up to $82 million in potential milestone payments plus tiered single to low double-digit royalties.

Quantifiable outcome

  • Single dose of EB-003 significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05) in validated preclinical PTSD model
  • +2 more outcomes

Companies that use Enveric Biosciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Enveric Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Enveric Biosciences partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • MagicMed IndustriescoreStrategic or Co-development Partner · 24 May 2021Enveric acquired MagicMed Industries in an all-stock transaction to expand its pipeline of cannabinoid and psychedelic therapies. MagicMed's Psybrary™ platform contributed to Enveric's discovery and development capabilities for creating psychedelic-derived molecules for oncology and CNS disorders including PTSD.
  • MycoMedica Life SciencescoreOEM/ Whitelabel/ Licensing PartnerLicensing agreement for EB-002, a topical product for radiation dermatitis. Deal terms include up to $62 million in potential milestone payments plus tiered single digit royalties.
  • Aries Science & TechnologycoreOEM/ Whitelabel/ Licensing PartnerLicensing agreement for Topical Product for Radiation Dermatitis. Deal terms include up to $61 million in potential milestone payments plus tiered royalties ranging from 2.5% to 10%.
  • Restoration Biologics LLCcoreOEM/ Whitelabel/ Licensing PartnerTwo licensing agreements for Cannabinoid-COX-2 conjugate compounds for pharmaceutical and potential non-pharmaceutical applications. Deal terms include up to $82 million in potential milestone payments plus tiered single to low double digit royalties.
  • TOTEC Pharma LLCminorOEM/ Whitelabel/ Licensing PartnerEnveric subsidiary Akos Biosciences licensed the RCANN trademark portfolio to TOTEC Pharma for development of patented cannabinoid crème technology for radiation dermatitis. Agreement grants option to purchase trademark portfolio upon meeting specific development and commercialization milestones.
  • Fish and Richardson P.C.coreImplementation/ SI/ Consulting PartnerIntellectual property law firm hired by Enveric to contest a Post-Grant Review petition filed by Gilgamesh Pharmaceuticals against Enveric's patent relevant to bretisilocin molecule acquired by AbbVie in $1.2 billion deal.
  • AbbVie Inc.minorOthersFollowing AbbVie's acquisition of Gilgamesh Pharmaceuticals in October 2025, AbbVie withdrew the Post-Grant Review petition filed by Gilgamesh against Enveric's patent covering halogenated psilocybin derivatives. This action left no remaining challenges against Enveric's patent.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Enveric Biosciences competitors and assessment

Company assessment

Direct peers

  • Compass Pathways: Clinical-stage company developing psilocybin therapy for treatment-resistant depression. Directly comparable to Enveric as a psychedelic-inspired CNS therapeutics developer targeting overlapping mental health indications, with later-stage assets.
  • MindMed: Clinical-stage neuroplastogenic medicine developer with a pipeline of LSD and MDMA-derived candidates for anxiety, depression, and ADHD. Closely comparable to Enveric's neuroplastogen CNS focus with similar target indications and small-molecule strategy.
  • atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health, including DMT-based treatments. Directly comparable to Enveric in psychedelic-inspired CNS drug development and out-licensing/partnering model.
  • GH Research: Clinical-stage company developing DMT-based therapies (GH001) for treatment-resistant depression. Comparable to Enveric's neuroplastogenic approach with overlapping 5-HT2A receptor mechanism and same TRD target indication.
  • Cybin Inc. Clinical-stage company developing deuterated psilocybin analogs (CYB003) for depression and other CNS indications. Directly comparable to Enveric's psychedelic-derived small-molecule CNS strategy and analogous chemistry-platform approach.
  • Sage Therapeutics: Developed Zurzuvae (zuranolone) for postpartum depression and other CNS neuroactive steroid therapies. Comparable to Enveric as a small-molecule CNS therapeutics developer targeting depression and related neuropsychiatric indications.
  • Axsome Therapeutics: Commercial-stage CNS biopharmaceutical company with Auvelity (dextromethorphan-bupropion) approved for major depressive disorder. Comparable to Enveric's CNS focus on depression/anxiety with an oral, outpatient prescription model analogous to Enveric's planned EB-003 positioning.
  • NRx Pharmaceuticals: Clinical-stage CNS company developing psychedelic-inspired treatments including NRX-101 for suicidal bipolar depression and DMT-based therapies. Directly comparable to Enveric in psychedelic-derived CNS therapeutics with overlapping TRD/suicidality target indications.

Broad incumbents

  • AbbVie: Large pharmaceutical company that acquired Gilgamesh Pharmaceuticals (bretisilocin) for ~$1.2B in October 2025, validating the psychedelic-inspired CNS therapeutic class. Comparable as a competitor/partner in the same therapeutic space and relevant acquirer for Enveric's patent estate.
  • Neumora Therapeutics: Clinical-stage CNS biopharmaceutical company developing precision neuroscience therapeutics for depression and other neuropsychiatric disorders. Comparable to Enveric as a CNS-focused small-molecule developer with similar target indications and prescription-model strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Enveric Biosciences social profiles

Digital presence

Enveric Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enveric Biosciences leadership team

Management profile

Number of profiles

Profiles4 records

Enveric Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Enveric Biosciences funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enveric Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enveric Biosciences

What does Enveric Biosciences do?

Enveric Biosciences is a pre-commercial biotechnology company developing neuroplastogenic small-molecule therapeutics for neuropsychiatric disorders. Its lead candidate EB-003 is designed to selectively engage 5-HT2A and 5-HT1B receptors to deliver fast-acting antidepressant and anxiolytic effects without hallucinogenic activity. The company leverages The Psybrary™ discovery platform to generate proprietary molecules, with multiple candidates out-licensed to pharmaceutical partners for development in radiation dermatitis, cannabinoid-COX-2 conjugates, and other indications.

Is Enveric Biosciences a public or private company?

Enveric Biosciences is a public company. It is classified as public and is currently operating.

When was Enveric Biosciences founded?

Enveric Biosciences was founded in 2021. It employs 11 to 50 people.

Where is Enveric Biosciences based?

Enveric Biosciences is headquartered in Cambridge, United States, in the North America region.

How does Enveric Biosciences make money?

Two revenue lines are on record. Licensing Revenue is the primary driver. The others are pharmaceutical Product Sales.

Who are Enveric Biosciences's main competitors?

Direct peers on record are Compass Pathways, MindMed, atai Life Sciences, GH Research, Cybin Inc., Sage Therapeutics, Axsome Therapeutics and NRx Pharmaceuticals. Broad incumbents are AbbVie and Neumora Therapeutics.

Does Enveric Biosciences have an API?

No public API is recorded for Enveric Biosciences.

What industry is Enveric Biosciences in?

Enveric Biosciences's product category is Psychiatric Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogEnveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate UpdateEnveric Biosciences reported a Q3 2026 net loss of $2.5 million, down from $3.4 million in Q3 2025, with cash on hand of $5.6 million. The company advanced EB-003 development, including a preclinical qEEG study and positive ADMET results, and secured a U.S. patent allowance for EVM401 derivatives.FinancialContent Business PageEnveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate UpdateEnveric Biosciences reported a Q3 2026 net loss of $2.5 million, down from $3.4 million in the prior year, with cash on hand of $5.6 million. The company advanced EB-003 development, including qEEG and ADMET studies, and secured a U.S. patent for its EVM401 Series. It plans to submit an IND application for EB-003.Business Wire BlogEnveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG StudyEnveric Biosciences reported preclinical qEEG study results for its lead candidate EB-003 in mice, showing modulation of brain-wave oscillations in prefrontal and parietal cortical regions. The study found EB-003 produced a neurophysiological profile differentiated from DMT, without inducing epileptiform activity or sedation. These findings support using qEEG as a pharmacodynamic biomarker in the planned first-in-human trial.Stock TitanEnveric EB-003 qEEG Study Shows Distinct Brain ActivityEnveric Biosciences reported preclinical qEEG study results for its lead candidate EB-003 in mice, showing modulation of brain-wave oscillations in prefrontal and parietal regions. The study found EB-003 produced a neurophysiological profile distinct from DMT, which induced epileptic-like EEG activity and spasms. The findings support using qEEG as a pharmacodynamic biomarker in the planned first-in-human trial.Financial PostEnveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET StudiesEnveric Biosciences announced positive results from completed ADMET studies for its lead candidate EB-003, a non-hallucinogenic neuroplastogenic compound. The in vitro screen showed favorable absorption, metabolism, and transporter properties, supporting its preclinical profile. The company plans to advance EB-003 toward a first-in-human clinical trial.Investing.comEnveric completes drug absorption studies for EB-003 candidateEnveric Biosciences completed in vitro absorption, distribution, metabolism, excretion, and toxicity studies for its EB-003 candidate. The studies showed favorable intestinal absorption, stability against liver enzymes, and no significant drug-drug interaction potential. The company plans a first-in-human trial but has not disclosed a timeline.Investing.comEnveric completes drug absorption studies for EB-003 candidateEnveric Biosciences completed in vitro absorption studies for its EB-003 candidate, showing favorable intestinal absorption and stability. The compound showed no significant plasma protein binding or drug-drug interaction potential. The company plans a first-in-human trial but has not disclosed a timeline.Stock TitanEnveric reports EB-003 preclinical results from 70+ testsEnveric Biosciences announced positive results from completed IND-enabling ADMET studies for its lead candidate EB-003, involving over 70 assays. The studies predicted favorable intestinal absorption, reduced drug-drug interaction potential, and stable liver metabolism. The company plans to advance EB-003 toward a first-in-human clinical trial.GurufocusEnveric Biosciences Secures New U.S. Patent Allowance for Next-GEnveric Biosciences received a USPTO Notice of Allowance for a patent on its EVM401 Series of non-hallucinogenic mescaline-derived neuroplastogens. This is the third allowance in the series, strengthening its IP estate for treating PTSD and other psychiatric conditions. The patent is expected to be issued soon.Financial PostEnveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 SeriesEnveric Biosciences received a USPTO Notice of Allowance for a patent on its EVM401 Series of non-hallucinogenic mescaline-derived neuroplastogens. This is the third allowance in the series, strengthening its IP estate. The patent covers composition-of-matter claims for methylone-inspired analogs designed to reduce hallucinogenic effects.